Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
UPDATE: CONVERGE-01 Trial Reports 83% PSA50 Response in Patients Without Prior Lu-PSMA
/in Clinical Trial, Metastatic, Phase 2/by MaxNew results from the phase 2 CONVERGE-01 trial, show preliminary antitumor activity of CONV01-α, an experimental PSMA-targeted alpha therapy, in patients with metastatic androgen pathway inhibitor-resistant prostate cancer (mCRPC) who had not previously received Lu-PSMA radioligand therapy. CONV01-α, also known as ²²⁵Ac-rosopatamab tetraxetan, combines the alpha-emitting isotope actinium-225 with a monoclonal antibody targeting PSMA. Unlike […]
UPDATE: Gedatolisib Plus Darolutamide Shows Activity in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUpdated results from the phase 1/2 CELC-G-201 trial (we talked about it in this previous article) provide new evidence of antitumor activity for gedatolisib combined with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs). Gedatolisib inhibits the PI3K–AKT–mTOR signaling pathway, which can contribute to resistance to […]
Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]
Phase 2 ExBAT Trial: AR Amplification Linked to Poorer Outcomes With Alternating Testosterone and Darolutamide
/in Clinical Trial, Metastatic, Phase 2/by MaxNew biomarker findings from the phase 2 ExBAT trial, suggest that androgen receptor (AR) amplification may be associated with poorer outcomes in patients receiving alternating bipolar androgen therapy (BAT) and darolutamide for metastatic castration-resistant prostate cancer (mCRPC). ExBAT/LACOG 0620 investigated an experimental strategy combining periods of supraphysiological testosterone exposure with subsequent androgen receptor inhibition. Patients […]
Phase 1 Trial: Astatine-211 PSMA-5 Shows Strong Early Responses in First-in-Human Prostate Cancer Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxEncouraging results suggest that 211At-PSMA-5, an experimental alpha-emitting radioligand targeting PSMA, may offer a promising new treatment approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human phase 1 study involving 15 patients whose disease had progressed following androgen receptor pathway inhibitors and taxane-based chemotherapy. Unlike established PSMA-targeted radioligand therapy […]
Phase 2 Trial: DLL3 PET Reveals Tumor Heterogeneity in Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxNew findings suggest that an experimental PET imaging technique targeting DLL3 could help identify neuroendocrine prostate cancer (NEPC) lesions and reveal important differences between metastases within the same patient. Neuroendocrine prostate cancer is an aggressive form of the disease that can emerge following prolonged treatment with androgen receptor-targeted therapies. These tumors frequently show reduced PSMA […]
Phase 1 Trial for SHR-4394: PSMA-Targeted ADC Shows Early Activity in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNew results provide encouraging preliminary evidence of antitumor activity for SHR-4394, an investigational antibody-drug conjugate (ADC) targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human 1hase 1 study evaluating SHR-4394 as a standalone treatment. The drug is designed to recognize PSMA, a protein frequently expressed on prostate cancer cells, and […]
UPDATE: TALAPRO-3, New Analysis Explores Talazoparib Benefit Across HRR Gene Mutations
/in Clinical Trial, Metastatic/by MaxNew exploratory biomarker findings from the phase 3 TALAPRO-3 trial, provide further insight into how patients with different DNA repair gene alterations respond to the combination of talazoparib and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC). TALAPRO-3 previously demonstrated a significant improvement in radiographic progression-free survival (rPFS) with the addition of the PARP inhibitor talazoparib […]